ARTICLE | Company News

Roche drug delivery, cancer news

January 25, 2010 8:00 AM UTC

Roche will invest CHF190 million ($185.1 million) in two of its production facilities to support manufacturing of an infusion-free delivery device for self-administering biological cancer medicines. Roche plans to use the device to deliver a subcutaneous formulation of cancer drug Herceptin trastuzumab. The subcutaneous formulation uses Enhanze recombinant human hyaluronidase ( rHuPH20) drug delivery technology from Halozyme Therapeutics Inc. (NASDAQ:HALO, San Diego, Calif.), which granted Roche rights to the technology in 2006. ...